NCT07664007Completed
Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma.
Effects of Nutritional Supplementation With Eicosapentaenoic Acid (EPA) on Body Composition and Systemic Pro-inflammatory and Pro-resolving Mediators in Patients Diagnosed With Unresectable Hepatocellular Carcinoma.
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
Dietary intervention with eicosapentaenoic acid combined with chemotherapy may shift inflammatory mediators toward resolution in non-resectable hepatocarcinoma and help to preserve muscle mass.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 8 May 2026
- Start date
- Mar 2019
- Primary completion date
- Sept 2023
- Lead sponsor
- Instituto de Investigación Sanitaria Aragón
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07664007
What you commit to
- Study type: Interventional
- Participants enrolled: 18
- From Mar 2019 to the primary completion date, Sept 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Drug abuse (except for alcohol).
- Any experimental therapy within 30 days prior to study entry.
Other illness
- Allergy to omega-3 acid or fish-derived products.
- Psychological or medical conditions that can interfere with study participation or the ability to provide informed consent.
Other
- Recurrent epistaxis
Who the study is looking for
- Participants diagnosed with unresectable HCC, candidates for systemic treatment with Sorafenib or similar agents.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Life expectancy \> 8 weeks.
- Not eligible for curative treatment (surgical resection/ablative therapy/liver transplantation).
- Not having a history of previous or concomitant malignancy except when a disease-free interval \> 5 years had been documented.
- Not receiving any other systemic antitumor agents (docetaxel, doxorubicin, irinotecan).
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Clínico Universitario Lozano Blesa. IIS Aragón Coordinator of this site? Confirm its status | Zaragoza | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.